FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to pharmaceutical industry, biotechnology and can be used to develop a dosage form of an antitumour agent with a wide spectrum of action. Disclosed is a pharmaceutical composition for treating malignant solid tumours, presented in the form of rectal suppositories, which contains a thallium-containing surface modified bacteriophage MS2 as an active component and a hydrophilic base in a weight ratio of 1:1.
EFFECT: invention provides preparing a dosage form of the preparation having high bioavailability and accelerated therapeutic effect.
1 cl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF POLY-SIGNAL ACTIVATION OF MALIGNANT SOLID TUMORS CELL APOPTOSIS | 2015 |
|
RU2599462C1 |
| ONCOLYTIC TREATMENT METHOD FOR BREAST CANCER | 2018 |
|
RU2695136C1 |
| METHOD FOR PRODUCING BACTERIOPHAGE HPV AND METHOD FOR PRODUCING MODIFIED BACTERIOPHAGE HPV | 2022 |
|
RU2790451C1 |
| METHOD OF PRODUCING VIRUS-LIKE BACTERIOPHAGE PARTICLE | 2024 |
|
RU2821694C1 |
| METHOD OF OBTAINING PARTICLES OF BACTERIOPHAGES OF LEVIVIRUS FAMILY | 2020 |
|
RU2811106C2 |
| SUPPOSITORY | 2000 |
|
RU2185817C2 |
| THERAPEUTIC AGENT FOR TREATING VIRAL HEPATITIS C | 2014 |
|
RU2568872C1 |
| MULTIFUNCTIONAL HYBRID RECOMBINANT PROTEIN MEDICINAL PRODUCTS FOR THE TREATMENT OF TUMOR DISEASES | 2022 |
|
RU2801367C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING NALBUPHINE HYDROCHLORIDE, USING IT FOR TREATING MODERATE TO SEVERE PAIN SYNDROME | 2012 |
|
RU2513514C1 |
| RECOMBINANT PLASMID pET-15b_T3_RL DNA PROVIDING SYNTHESIS OF RECOMBINANT FUSION PROTEIN CONSISTING OF TUMOR-SPECIFIC PEPTIDES AND ANTITUMOR PEPTIDE RL2, AND RECOMBINANT FUSION PROTEIN POSSESSING ANTI-TUMOR ACTIVITY AGAINST HUMAN BREAST CANCER | 2016 |
|
RU2619053C1 |
